It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Understanding the factors that influence people’s decisions regarding vaccination is essential to promote vaccination. We aimed to clarify the motivations for receiving booster vaccines. We conducted a paper-based questionnaire distributed during January–February 2022 involving students and faculty staff who received the first COVID-19 vaccination at the mass vaccination program during June–September 2021 at Keio University. A total of 1725 participants were enrolled, and all completed the survey. Among these, 64.9% reported a significant adverse event (AEs) affecting daily life after the second vaccine. “Fear of severe COVID-19 illness” (72.6%) was the most common reason for getting vaccinated, followed by “concern of infecting others” (68.4%) and “fear of COVID-19 infection itself” (68.3%). Television emerged as the most influential source of information (80%), followed by university information (50.2%) and social networking sites (42.8%). Multivariate analysis revealed “fear of severe COVID-19 illness”, “fear of COVID-19 infection itself”, and “trust in the efficacy and safety of the vaccines in general” were significantly correlated with willingness to receive paid vaccinations. The severity of AEs and source of information were not related to participants’ willingness to receive booster vaccinations. Participants with positive reasons for vaccination were more likely to accept a third dose.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Keio University School of Medicine, Department of Infectious Diseases, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
2 Keio University Hospital, Biostatistics Unit, Clinical and Translational Research Center, Tokyo, Japan (GRID:grid.412096.8) (ISNI:0000 0001 0633 2119); Keio University, Graduate School of Health Management, Kanagawa, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
3 Keio University School of Medicine, Department of Infectious Diseases, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Keio University School of Medicine, Department of Laboratory Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
4 Keio University Health Center, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
5 Keio University School of Medicine, Department of Infectious Diseases, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Keio University Faculty of Pharmacy, Division of Pharmacodynamics, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
6 Keio University Hospital, Biostatistics Unit, Clinical and Translational Research Center, Tokyo, Japan (GRID:grid.412096.8) (ISNI:0000 0001 0633 2119)
7 Keio University School of Medicine, Department of Surgery, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)